Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer

Abstract Although the emergence of immunotherapy has broken the deadlock of extensive stage small cell lung cancer (ES‐SCLC), the study of markers for predicting efficacy is the key to the breakthrough of immunotherapy, and exploring more innovative, efficient and safe treatment models is also an im...

Full description

Bibliographic Details
Published in:	Thoracic Cancer
Main Authors:	Yanan Cui, Peiyan Zhao, Ying Cheng, Xiubao Ren
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Subjects:	extensive stage small cell lung cancer immunotherapy natural killer cells
Online Access:	https://doi.org/10.1111/1759-7714.14837

Similar Items

Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer  in the Era of Immunotherapy
by: Tingting CHEN, et al.
Published: (2025-05-01)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
by: Lijuan Li, et al.
Published: (2023-04-01)

Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells
by: Zhenzhen eHui, et al.
Published: (2015-12-01)

Development of a prognostic model for patients with extensive-stage small cell lung cancer undergoing immunotherapy and chemotherapy
by: Yunbin Gao, et al.
Published: (2025-03-01)

Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients
by: Jianan Li, et al.
Published: (2024-08-01)

Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy
by: Yunfeng Wang, et al.
Published: (2025-06-01)

Factors affecting survival and prognosis in extensive stage small cell lung cancer
by: Mert Erciyestepe, et al.
Published: (2025-04-01)

Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study
by: Jorge Raul azquez-Urrutia, et al.
Published: (2025-05-01)

The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy
by: Ya Zhang, et al.
Published: (2024-12-01)

Meta‐analysis of PD‐(L)1 inhibitor plus chemotherapy versus chemotherapy as first‐line treatment in extensive‐stage small‐cell lung cancer
by: Jiangyue Lu, et al.
Published: (2023-09-01)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
by: Huanhuan Li, et al.
Published: (2023-08-01)

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer
by: Tong Chen, et al.
Published: (2024-09-01)

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
by: Ke Zhao, et al.
Published: (2025-03-01)

Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
by: Guo Lin, et al.
Published: (2023-05-01)

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
by: Li Liu, et al.
Published: (2023-07-01)

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients
by: Li‐Ling Huang, et al.
Published: (2021-07-01)

Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study
by: Bertrand Mennecier, et al.
Published: (2024-04-01)

Treatment patterns and clinical outcomes in 157 patients with extensive-stage small cell lung cancer: real-world evidence from a single-center retrospective study
by: Yumin Zheng, et al.
Published: (2023-12-01)

Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study
by: Meiling Sun, et al.
Published: (2024-09-01)

Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge
by: Yang H, et al.
Published: (2025-05-01)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021-04-01)

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
by: Tianming Zhang, et al.
Published: (2023-06-01)

Extensive‐stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?
by: Yuanhu Yao, et al.
Published: (2023-06-01)

Immune killer cells treatment for previously treated stage IV NSCLC patients
by: Yen-Han Tseng, et al.
Published: (2024-08-01)

Breakthroughs in dendritic cell-cytokine-induced killer therapy for non-small cell lung cancer
by: Liu Ruoshui, et al.
Published: (2025-03-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

Local radiotherapy in extensive-stage small-cell lung cancer sustainably boosts the clinical benefit of first-line immunotherapy: a case report
by: Hongming Wang, et al.
Published: (2024-11-01)

Differential expression of the MYC‐Notch axis drives divergent responses to the front‐line therapy in central and peripheral extensive‐stage small‐cell lung cancer
by: Libo Luo, et al.
Published: (2025-03-01)

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
by: Eisuke Mochizuki, et al.
Published: (2025-01-01)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
by: Chaoyuan Liu, et al.
Published: (2023-06-01)

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis
by: Jiayi Tang, et al.
Published: (2024-11-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022-10-01)

Preliminary Results of Clinical Experience with Consolidative High-Dose Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
by: Hakyoung Kim, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2024-01-01)

Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review
by: Tao Wang, et al.
Published: (2023-06-01)

Prognostic value of pretreatment procalcitonin and neutrophil–lymphocyte ratio in extensive-stage small-cell lung cancer
by: Dongfang Chen, et al.
Published: (2024-12-01)

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project
by: Alzbeta Bejckova, et al.
Published: (2025-09-01)

Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report
by: Freeman Paczkowski, et al.
Published: (2024-06-01)

The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data
by: Shuang Zhang, et al.
Published: (2024-07-01)